Security
Alvotech Warrant · ALVOW
ALVOWNASDAQWarrantCurrentCIK 1898416Updated Oct 15, 2026
Name history
Alvotech Lux Holdings S.A.S. · through May 2, 2022
ALVOW price & chart
Loading TradingView…
NASDAQ:ALVOW on TradingView ↗About the company
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||
| Profit or LossUSD | — | — | 27,919,000Source | -231,864,000Source | -551,731,000Source | -513,580,000Source |
| Cash flows from financing activities: | ||||||
| Dividends paid | — | — | —Source | — | —Source | —Source |
| Additional Financial Items | ||||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | — | -80,000Source | -48,000Source | -60,000Source | -115,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | — | — | 93,182,000Source | -119,063,000Source | -8,320,000Source | -3,576,000Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | — | — | -30,872,000Source | 5,916,000Source | -10,718,000Source | 15,269,000Source |
| AdjustmentsForFinanceCostsUSD | — | — | 149,190,000Source | 303,165,000Source | 267,157,000Source | — |
| AdjustmentsForFinanceIncomeUSD | — | — | 198,492,000Source | 80,145,000Source | 4,823,000Source | — |
| AdjustmentsForIncomeTaxExpenseUSD | — | — | 108,429,000Source | 14,301,000Source | -99,318,000Source | -38,067,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | 7,378,000Source | 7,626,000Source | 18,033,000Source | 10,317,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | 16,841,000Source | -8,161,000Source | 5,183,000Source | -10,566,000Source |
| GeneralAndAdministrativeExpenseUSD | — | — | 90,946,000Source | 65,713,000Source | 76,559,000Source | 186,742,000Source |
| GoodwillUSD | 12,790,000Source | 11,692,000Source | 12,835,000Source | 11,330,000Source | 12,058,000Source | 11,643,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | 58,950,000Source | 54,921,000Source | 57,254,000Source | 35,372,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | — | 2,387,000Source | 4,617,000Source | 3,649,000Source | 568,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 233,482,000Source | 896,263,000Source | 278,831,000Source | 193,678,000Source |
| ProceedsFromIssuingSharesUSD | — | — | — | — | 0Source | 9,800,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | — | — | 0Source | 0Source | 133,000Source | 379,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 31,659,000Source | 3,339,000Source | 13,239,000Source | 11,122,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 25,419,000Source | 749,082,000Source | 99,367,000Source | 34,714,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.24Source | 0.25Source | 0.25Source | 0.25Source |
| AuditorsRemunerationForTaxServicesUSD | 882,000Source | 279,000Source | 462,000Source | 676,000Source |
| AverageEffectiveTaxRatenumber | 0.8Source | -0.07Source | 0.15Source | 0.07Source |
| BasicEarningsLossPerShareUSD per share | 0.1Source | -0.87Source | -2.43Source | -2.6Source |
| CurrentTaxExpenseIncomeUSD | 1,906,000Source | 1,149,000Source | 1,307,000Source | 1,015,000Source |
| DeferredTaxExpenseIncomeUSD | 137,476,000Source | 7,284,000Source | -89,847,000Source | -54,236,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | 106,655,000Source | 13,205,000Source | -100,567,000Source | 38,919,000Source |
| DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | 37,851,000Source | 31,301,000Source | 25,989,000Source | 23,164,000Source |
| DepreciationRightofuseAssetsUSD | 14,485,000Source | 13,377,000Source | 8,913,000Source | -9,869,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.1Source | -0.87Source | -2.43Source | -2.6Source |
| EmployeeBenefitsExpenseUSD | 194,009,000Source | 154,026,000Source | 164,909,000Source | 135,440,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 7,378,000Source | 7,626,000Source | 18,033,000Source | 10,317,000Source |
| FinanceCostsUSD | 149,190,000Source | 303,165,000Source | 267,157,000Source | 188,419,000Source |
| FinanceIncomeUSD | 198,492,000Source | 80,145,000Source | 4,823,000Source | 2,549,000Source |
| GeneralAndAdministrativeExpenseUSD | 90,946,000Source | 65,713,000Source | 76,559,000Source | 186,742,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 108,429,000Source | 14,301,000Source | -99,318,000Source | -38,067,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 9,238,000Source | 6,614,000Source | 3,840,000Source | 6,022,000Source |
| OtherEmployeeExpenseUSD | 20,804,000Source | 19,998,000Source | 19,718,000Source | 11,670,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 14,698,000Source | 11,168,000Source | 11,518,000Source | 10,052,000Source |
| ProfitLossBeforeTaxUSD | 136,348,000Source | -217,563,000Source | -651,049,000Source | -551,647,000Source |
| ProfitLossFromOperatingActivitiesUSD | 78,207,000Source | 69,644,000Source | -354,860,000Source | -346,442,000Source |
| ResearchAndDevelopmentExpenseUSD | 184,193,000Source | 171,312,000Source | 210,827,000Source | 180,622,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | -0.01Source | 0.01Source | -0.03Source | -0.02Source |
Filing attachments
c116686_ex99-1.htm · 6-K · 2026-06-17
Exhibit 99.1 Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares REYKJAVIK, ICELAND (June 15, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). In addition, Alvotech expects to gra…
Read attachment ↗c116686_ex99-2.htm · 6-K · 2026-06-17
Exhibit 99.2 Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement REYKJAVIK, ICELAND (June 16, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an …
Read attachment ↗a20251231-ex425amendedandr.htm · 20-F · 2026-03-31
Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” AMENDMENT NO. 5 TO TERM LOAN CREDIT AGREEMENT This AMENDMENT NO. 5 TO TERM LOAN CREDIT AGREEMENT, dated as of December 31, 2025 (this “Agreement”), among Alvotech, S.A., a public limited liability company (société anonyme) incorporated and existing under the laws…
Read attachment ↗a20251231-ex426superpriori.htm · 20-F · 2026-03-31
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” $100,000,000 SUPER-PRIORITY CREDIT AGREEMENT Dated as of December 31, 2025 among ALVOTECH, S.A., as the Borrower, GLAS USA LLC, as Administrative Agent, GLAS AMERICAS LLC, as Collateral Agent, and THE LENDERS PARTY HERETO FOR THE PURPOSES OF SECTIONS 1272, 1273 AND 1275…
Read attachment ↗